TNFRSF17 and plasma cell myeloma: Given its specific overexpression in myeloma cells and limited presence in normal cells, BCMA is an effective target for therapies like antibody–drug conjugates, bispecific T-cell engagers (TCEs), and CAR-T cell therapies [27, 67, 149, 150].